Truist Securities raised its price target on CG Oncology shares to $82 from $77, maintaining a Buy rating. The stock trades at $74, near its 52-week high, after a 206% surge over the past year.
The firm hosted a key opinion leader lunch on non-muscle invasive bladder cancer dynamics. Intermediate-risk NMIBC is seen as a chronic management paradigm with interest in emerging therapies.
Durability is the key adoption driver, with ~80% 24-month duration of response as a crucial differentiator. High-risk NMIBC is likely fragmented, with potential for more lines before cystectomy.
Real-world factors like workflow, reimbursement, and convenience matter. Truist is encouraged on cretostimogene ahead of the PIVOT-006 readout in H1 2026.
In other news, UBS, RBC, BofA, and Truist updated targets. CG Oncology appointed Jim DeTore as CFO.
